Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048-3058, 2014
Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3067, 2014
Bennani-Baiti B, Yadav S, Flynt L, et al: Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol 33:1216, 2015
Mitsuhashi K, Momose M, Masuda A, et al: Positron emission tomography revealed diffuse involvement of the lower legs and occult extracutaneous lesions in subcutaneous panniculitis-like T-cell lymphoma. Clin Nucl Med 38:209-211, 2013
Kim JS, Jeong YJ, Sohn MH, et al: Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: Disease extent and treatment response evaluation. Radiol Oncol 46:279-283, 2012
Uematsu T, Kasami M: 3T-MRI, elastography, digital mammography, and FDG-PET CT findings of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) of the breast. Jpn J Radiol 30:766-771, 2012
Kwok G, Loong F, Wong CS, et al: Macrophage activation syndrome leading to fatality in subcutaneous panniculitis-like T cell lymphoma. Ann Hematol 93:873-875, 2014
Babb A, Zerizer I, Naresh KN, et al: Subcutaneous panniculitis-like T-cell lymphoma with extracutaneous dissemination demonstrated on FDG PET/CT. Am J Hematol 86:375-376, 2011
Adams HJA, Kwee TC: Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma. J Clin Oncol 33:1217, 2015
Adams HJ, Kwee TC, de Keizer B, et al: FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: Systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 41:565-574, 2014
Khan AB, Barrington SF, Mikhaeel NG, et al: PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122:61-67, 2013
Cerci JJ, Györke T, Fanti S, et al: Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med 55:1591-1597, 2014
Berthet L, Cochet A, Kanoun S, et al: In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54:1244-1250, 2013
Muslimani AA, Farag HL, Francis S, et al: The utility of 18-Ffluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol 31:409-412, 2008
Schaefer NG, Strobel K, Taverna C, et al: Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34:60-67, 2007
Adams HJ, Kwee TC, de Keizer B, et al: Systematic review and metaanalysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: Is bone marrow biopsy still necessary? Ann Oncol 25:921-927, 2014
Hong J, Lee Y, Park Y, et al: Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol 91:687-695, 2012
Adams HJ, Kwee TC, Fijnheer R, et al: Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol 89:726-731, 2014
Sehn LH, Scott DW, Chhanabhai M, et al: Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29:1452-1457, 2011
Campbell J, Seymour JF, Matthews J, et al: The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76:473-480, 2006
Laffon E, Marthan R: Quantitative positron emission tomography imaging for response assessment of [18F]fluorodeoxyglucose-avid lymphomas: Should we report standard uptake value confidence limits? J Clin Oncol 33:1218, 2015
Itti E, Juweid ME, Haioun C, et al: Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: Importance of the reference background. J Nucl Med 51:1857-1862, 2010
Hawkes EA, Chong G, Grigg A: Diagnostic medical radiation exposure in surveillance of aggressive lymphoma: Clinical trial design should reflect clinical practice. J Clin Oncol 33:1219, 2015
Cheah CY, Hofman MS, Dickinson M, et al: Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109:312-317, 2013
Lynch RC, Zelenetz AD, Armitage JO, et al: Surveillance imaging for lymphoma: Pros and cons. Am Soc Clin Oncol Educ Book e388-e395, 2014
El-Galaly TC, Mylam KJ, Bøgsted M, et al: Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 89:575-580, 2014
Pingali SR, Jewell SW, Havlat L, et al: Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer 120:2122-2129, 2014
Thompson CA, Ghesquieres H, Maurer MJ, et al: Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 32:3506-3512, 2014
US Food and Drug Administration: Initiative to reduce unnecessary radiation exposure from medical imaging. http://www.fda.gov/Radiation-Emitting Products/RadiationSafety/RadiationDoseReduction/ucm2007191.htm
